Fibrobiologics Inc.

FibroBiologics reports that a preclinical animal study detected cartilage tissue at the treatment site within four weeks after a single injection of fibroblast-spheroid–derived chondrocyte spheroids (FSdCS). According to the company, FSdCS can be produced within four days and are designed for direct injection into damaged joints. FibroBiologics cites more than 270 patents and views the treatment as a potentially cost-effective alternative to joint replacement surgery; however, the results are preliminary and come from animal studies. » More on de.investing.com

FibroBiologics completed a private placement and raised approximately $3.0 million gross from the sale of 4,081,633 common shares or pre-funded warrants at $0.735 each. In addition, five-year Series A warrants and short-term Series B warrants (18 months) were issued, which together could bring in a further approximately $6.0 million if fully exercised for cash. The securities were offered pursuant to Section 4(a)(2); a registration statement for resale is to be filed. FibroBiologics intends to use the net proceeds for working capital and general corporate purposes; the company most recently reported negative cash flow of $15.7 million and is described as being in weak financial condition. » More on de.investing.com

FibroBiologics has enrolled the first patients in a randomized, multicenter phase‑1/2 study in Australia that will recruit up to 120 participants to test CYWC628, a topically applied allogeneic fibroblast‑spheroid therapy. The trial will assess safety, tolerability and efficacy of low and high doses plus standard care versus standard care alone; an interim analysis of the primary safety and efficacy endpoints is planned after six weeks. The company calls this a clinical milestone, while the stock is trading well below its 52‑week high. » More on de.investing.com